From bench to bedside
Check out the 5 must-read stories on how incubators are shaping early drug development.
Given the dearth of innovation, high real estate prices and emphasis on drug pricing, the need has grown to accelerate early drug development. Big pharma, along with private partners, has been finding new ways to team up with academia to bring drugs from bench to bedside. And incubators are increasingly becoming an important part of that ecosystem.
BioPharma Dive has explored the way new partnerships and incubators are shaping early drug development. Check out our top content on the topic:
Pharma has struggled to find innovation and academics have a poor track record moving compounds forward. Now other players are bridging the gap. Read More >>
High real-estate costs. Scarce lab space. Access to capital. Incubators are ramping up support to help emerging biotechs avoid common pain points. Read More >>
A handful of people stand out as significant figures in a small community that promotes biotech growth. Read More >>
BioPharma Dive spoke to a number of biotechs about how incubators can help solve the problems faced in early drug development. Here's what they said. Read More >>
Founded last year, Mass Innovation Labs styles itself as a “chief operating officer” for emerging companies. Read More >>
Follow Lisa LaMotta on Twitter